TickerGuard
Buy Day today: Neutral (55) Mixed market breadth · no major macro event
BNTC

Benitec Biopharma Ltd

Healthcare · Biotechnology

8.40$ -1.1% vs. previous close Closing price · As of: Nov 3, 2026

Ownership

Ownership Structure

Who owns Benitec Biopharma Ltd (BNTC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 52.9% of the shares are freely tradable; institutional investors hold 98.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 98.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.7%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 52.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 10.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 35Mio.

Largest Shareholders

Institutions

Institutions BNTC
Name Stake (%) Shares Change (%) Date
Suvretta Capital Management, LLC 33.11 11,548,351 +0.0 06/30/2026
Nantahala Capital Management, LLC 8.53 2,976,742 +107.0 06/30/2026
HHG PLC 8.25 2,876,380 -1.2 03/31/2026
Jupiter Topco LLC 7.11 2,478,547 +0.0 06/30/2026
Franklin Templeton Inc 6.92 2,412,888 +1.5 06/30/2026
Adage Capital Partners Gp LLC 6.08 2,120,672 +0.0 06/30/2026
RA Capital Management, LLC 5.30 1,850,000 +0.0 06/30/2026
BlackRock Inc 4.03 1,407,138 +18.7 06/30/2026

Funds

Funds BNTC
Name Stake (%) Shares Change (%) Date
HBM Healthcare Investments AG Ord 3.48 1,191,669 +0.0 06/30/2026
Simplify Health Care ETF 2.93 1,002,201 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?